Product Description
Mechanisms of Action: NK2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major|Generalized anxiety disorder|Depressive Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12616000412437p |
MC1952 | N/A |
Not yet recruiting |
Skin Cancer |
2017-10-01 |
|||
2007-003863-31 |
COMPASS | P3 |
Completed |
Depressive Disorder, Major |
2009-02-27 |
2022-03-12 |
Treatments |
|
NCT00629551 |
COMPASS | P3 |
Completed |
Depressive Disorder, Major |
2009-02-01 |
2019-03-18 |
Treatments |
|
2007-003159-36 |
2007-003159-36 | P3 |
Completed |
Depressive Disorder, Major |
2009-01-14 |
2025-06-26 |
Treatments |
|
NCT00531622 |
EFC10290 | P3 |
Completed |
Depressive Disorder, Major |
2009-01-01 |
2019-03-21 |
Treatments |
|
2006-003793-94 |
2006-003793-94 | P3 |
Completed |
Depressive Disorder, Major |
2008-06-04 |
2022-03-12 |
Treatments |
|
2006-003805-19 |
2006-003805-19 | P3 |
Completed |
Generalized anxiety disorder |
2008-04-03 |
2022-03-12 |
Treatments |
|
NCT00417118 |
EFC5583 | P3 |
Completed |
Generalized anxiety disorder |
2008-04-01 |
2019-03-21 |
Treatments |
|
NCT00336713 |
MAGENTA | P3 |
Completed |
Depressive Disorder |
2008-04-01 |
2019-03-21 |
Treatments |
|
NCT00390533 |
EFC5582 | P3 |
Completed |
Generalized anxiety disorder |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00415142 |
EFC5574 | P3 |
Completed |
Depressive Disorder, Major |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00390650 |
EFC5581 | P3 |
Completed |
Generalized anxiety disorder |
2007-11-01 |
2019-03-21 |
Treatments |
|
NCT00250601 |
EFC5571 | P3 |
Completed |
Depressive Disorder |
2007-07-01 |
2019-03-21 |
Treatments |
|
NCT00429260 |
SFY6577 | P3 |
Completed |
Depressive Disorder |
2007-06-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00250653 |
LTS5577 | P3 |
Completed |
Depressive Disorder |
2007-04-01 |
2019-03-21 |
Treatments |
|
2004-002327-41 |
2004-002327-41 | P3 |
Completed |
Depressive Disorder, Major |
2006-12-29 |
2022-03-12 |
Treatments |
|
2004-002328-16 |
2004-002328-16 | P3 |
Completed |
Depressive Disorder, Major |
2006-12-26 |
2022-03-12 |
Treatments |
|
NCT00250627 |
EFC5573 | P3 |
Completed |
Depressive Disorder |
2006-12-01 |
2019-03-21 |
Treatments |
|
NCT00256113 |
EFC5575 | P3 |
Completed |
Depressive Disorder |
2006-12-01 |
2019-03-21 |
Treatments |
|
NCT00250614 |
EFC5572 | P3 |
Completed |
Depressive Disorder |
2006-10-01 |
2019-03-21 |
Treatments |